IMUC (EOM Pharmaceutical Holdings) Cyclically Adjusted FCF per Share: $0.00 (As of Jun. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EOM Pharmaceutical Holdings Cyclically Adjusted FCF per Share?

EOM Pharmaceutical Holdings IMUC Cyclically Adjusted FCF per Share is $0.00 as of Jun. 2018.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

EOM Pharmaceutical Holdings's adjusted free cash flow per share for the three months ended in Jun. 2018 was $-0.519. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Jun. 2018.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-29), EOM Pharmaceutical Holdings's current stock price is $0.1301. EOM Pharmaceutical Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2018 was $0.00. EOM Pharmaceutical Holdings's Cyclically Adjusted Price-to-FCF of today is .


EOM Pharmaceutical Holdings  (OTCPK:IMUC) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


EOM Pharmaceutical Holdings Cyclically Adjusted FCF per Share Related Terms


EOM Pharmaceutical Holdings Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for EOM Pharmaceutical Holdings's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EOM Pharmaceutical Holdings Cyclically Adjusted FCF per Share Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IMUC vs MNTMD, RTTR, BZYR: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's Cyclically Adjusted Price-to-FCF falls into.



EOM Pharmaceutical Holdings Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, EOM Pharmaceutical Holdings's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2018 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2018 (Change)*Current CPI (Jun. 2018)
=-0.519/251.9890*251.9890
=-0.519

Current CPI (Jun. 2018) = 251.9890.

EOM Pharmaceutical Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200809 -14.156 218.783 -16.305
200812 -13.281 210.228 -15.919
200903 -16.438 212.709 -19.474
200906 -24.188 215.693 -28.258
200909 -15.757 215.969 -18.385
200912 -7.243 215.949 -8.452
201003 -18.297 217.631 -21.186
201006 -23.625 217.965 -27.313
201009 -28.321 218.439 -32.671
201012 -17.426 219.179 -20.035
201103 -25.787 223.467 -29.078
201106 -17.958 225.722 -20.048
201109 -21.619 226.889 -24.011
201112 -25.056 225.672 -27.978
201203 -38.967 229.392 -42.806
201206 -33.110 229.478 -36.358
201209 -22.752 231.407 -24.776
201212 -25.742 229.601 -28.252
201303 -17.109 232.773 -18.521
201306 -14.477 233.504 -15.623
201309 -14.036 234.149 -15.105
201312 -19.112 233.049 -20.665
201403 -18.181 236.293 -19.389
201406 -18.514 238.343 -19.574
201409 -16.691 238.031 -17.670
201412 -13.433 234.812 -14.416
201503 -15.646 236.119 -16.698
201506 -17.097 238.638 -18.054
201509 -28.668 237.945 -30.360
201512 -25.735 236.525 -27.418
201603 -23.487 238.132 -24.854
201606 -25.185 241.018 -26.331
201609 -16.267 241.428 -16.979
201612 -10.538 241.432 -10.999
201703 -17.099 243.801 -17.673
201706 -9.727 244.955 -10.006
201709 -1.450 246.819 -1.480
201712 -1.176 246.524 -1.202
201803 -0.382 249.554 -0.386
201806 -0.519 251.989 -0.519

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.00 mean?
EOM Pharmaceutical Holdings (IMUC) has a Cyclically Adjusted FCF per Share of $0.00 as of Jun. 2018. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' Cyclically Adjusted FCF per Share too high?
EOM Pharmaceutical Holdings' current Cyclically Adjusted FCF per Share is $0.00.
How does EOM Pharmaceutical Holdings' Cyclically Adjusted FCF per Share compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' Cyclically Adjusted FCF per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on EOM Pharmaceutical Holdings and its competitors. EOM Pharmaceutical Holdings's current Cyclically Adjusted FCF per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current Cyclically Adjusted FCF per Share of $0.00. The current Cyclically Adjusted FCF per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current Cyclically Adjusted FCF per Share is $0.00 as of Jun. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EOM Pharmaceutical Holdings Business Description

Address 136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.